September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.

September 22, 2022 — The recipient of the TCT 2022 Thomas J. Linnemeier “Spirit of Interventional Cardiology” Young Investigator Award is Jennifer Rymer, MD, MBA, MHS, John Bush Simpson Assistant Professor of Medicine at the Duke University Medical Center, Durham, NC. The award was announced Sept.

September 20, 2022 — Orchestra BioMed, Inc., a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies, announced the presentation of positive long-term clinical results from the MODERATO II Control Patients Crossover Extension Study of 

September 20, 2022 — Medtronic, a global leader in healthcare technology, today announced the LINQ II Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S.

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the 

September 19, 2022 —  Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., H

September 19, 2022 — Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as the winner of the TCT 2022 Innovation Shark Tank Competition.

September 19, 2022 —  A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has demonstrated significant improvement in cardiac output, left ventricular end diastolic pressure, and urine output in patients with

September 19, 2022 —  HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) patch monitor intended for detection of acute coronary syndr

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now